Graft Versus Host Disease Treatment Market: Global Market Size, Dynamics, Regional Share, Trends, Competitor Analysis 2015 to 2020 and Forecast 2021 to 2027

$ PRICE - $ 3,000.00$ 8,900.00

Graft Versus Host Disease Treatment Market: by Product Type (Monoclonal Antibodies, Tyrosine Kinase Inhibitors, Thalidomide, and mTOR Inhibitors), By Disease Type (Acute Graft vs. Host Disease (aGvHD), Chronic Graft vs. Host Disease (cGvHD)), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and Geography

 

$ PRICE - $ 3,000.00$ 8,900.00
Clear selection
Clear
$ PRICE - $ 3,000.00$ 8,900.00
FacebookTwitterLinkedinEmail

Report

Description

The global graft versus host disease treatment market expected to grow at a CAGR of 7.08% during the forecast period 2021-2027. Graft versus host disease is an immune-mediated disease. It is the medical complication in which there would be a complex interaction between the donor and the adaptive immunity of the recipient. The disease occurs when the bone marrow or the stem cells are transplanted. The treatment using the stem cells and bone marrow are used in the reconstruction of the damaged cells which surround the cancer cells. It is also used in the during solid organ transplantation. The chances of developing graft versus host disease is more in the allogeneic transplantation.

Graft Versus Host Disease Treatment Market

MARKET SUMMARY
-
7.08% CAGR
  • Study Period– 2021 – 2027
  • Base Year– 2020
  • CAGR– 7.08%
  • Largest Market– North-America
  • Fastest Growing Market– Asia-Pacific

Graft Versus Host Disease Treatment Market

  • The report on global graft versus host disease treatment market gives historical, current and future market sizes (US$ Bn) based on product type, disease type, distribution channel and region.
  • graft versus host disease treatment market report gives comprehensive outlook across the region with special emphasis on key regions such as North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
Key Players
  • Novartis AG
  • Merck & Co.
  • Soligenix, Inc.
  • Mesoblast Ltd
  • Sanofi
Graft Versus Host Disease Treatment Market

Drivers And Restraints

Rising count of the allogeneic hematopoietic stem cell transplant and increase in the prevalence of cancer patients are majorly driving the growth of graft versus host disease treatment market. The increasing bone marrow transplantations for various types of cancers is likely to drive the growth of the market. The growing R&D activities is helping in fastening up the drug development process which is expected to add fuel for the growth of the market. However, the higher investment in the initial stages of the clinical trials is likely to hamper the growth of the market. The strict government regulations for approvals is also hindering the growth of the graft versus host disease treatment market.


North-America got significant share

Graft Versus Host Disease Treatment Market

Geographically, global market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East and Africa. North America graft versus host disease treatment market growing due to increase in the prevalence of cancer. The rising count of the bone transplantations is also considerably high in this region. The increasing healthcare expenditure and adoption of the modern treatment options are adding scope for the growth of the market in this region.

Latin America
Latin-America
North-America
North-America
Europe
Europe
Asia Pacific
Asia-Pacific
Middle East
Middle East

Key

Notable Market Developments

  • In November 2017, Merck & Co., Inc. received FDA Approval of PREVYMIS (letermovir) for Prevention of Cytomegalovirus (CMV) Infection and Disease in Adult Allogeneic Stem Cell Transplant Patients

Key

Key Features of the Report

Graft Versus Host Disease Treatment Market Segmentation


Location

GEOGRAPHY


Report

Table Of Content

Table of Content

  1. Executive Summary
  2. Global Graft Versus Host Disease (GVHD) Market Introduction
    • Global Graft Versus Host Disease (GVHD) Market – Taxonomy
    • Global Graft Versus Host Disease (GVHD) Market –Definitions
      • Product Type
      • Disease Type
      • Route of Administration
  1. Global Graft Versus Host Disease (GVHD) Market Dynamics
    • Drivers
    • Restraints
    • Opportunities/Unmet Needs of the Market
    • Trends
    • Global Graft Versus Host Disease (GVHD) Market Dynamic Factors – Impact Analysis
    • Global Graft Versus Host Disease (GVHD) Market – Competition Landscape
    • Epidemiology
  2. Global Graft Versus Host Disease (GVHD) Market Analysis, 2012 – 2017 and Forecast, 2018 – 2023
    • Market Analysis, 2012 – 2017 and Forecast, 2018 – 2023 (Revenue, USD Mn)
    • Year-over-Year (Y-o-Y) Growth Analysis (%)
    • Market Opportunity Analysis
  3. Global Graft Versus Host Disease (GVHD) Market, By Product Type, 2012 – 2017 and Forecast, 2018 – 2023 (Revenue, USD Mn)
    • Monoclonal Antibodies (mAB)
      • Market Analysis, 2012 – 2017 and Forecast, 2018 – 2023 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Tyrosine Kinase Inhibitors
      • Market Analysis, 2012 – 2017 and Forecast, 2018 – 2023 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • mTOR inhibitors
      • Market Analysis, 2012 – 2017 and Forecast, 2018 – 2023 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Etanercept
      • Market Analysis, 2012 – 2017 and Forecast, 2018 – 2023 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Thalidomide
      • Market Analysis, 2012 – 2017 and Forecast, 2018 – 2023 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
  1. Global Graft Versus Host Disease (GVHD) Market Forecast, By Disease Type, 2012 – 2017 and Forecast, 2018 – 2023
    • Acute graft vs. host disease (aGvHD)
      • Market Analysis, 2012 – 2017 and Forecast, 2018 – 2023 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Chronic graft vs. host disease (cGvHD)
      • Market Analysis, 2012 – 2017 and Forecast, 2018 – 2023 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
  1. Global Graft Versus Host Disease (GVHD) Market Forecast, By Route of Administration, 2012 – 2017 and Forecast, 2018 – 2023
    • Oral
      • Market Analysis, 2012 – 2017 and Forecast, 2018 – 2023 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Parenteral
      • Market Analysis, 2012 – 2017 and Forecast, 2018 – 2023 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
  1. Global Graft Versus Host Disease (GVHD) Market Forecast, By Region, 2012 – 2017 and Forecast, 2018 – 2023 (Revenue, USD Mn)
    • North America
      • Market Analysis, 2012 – 2017 and Forecast, 2018 – 2023 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Europe
      • Market Analysis, 2012 – 2017 and Forecast, 2018 – 2023 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Asia-Pacific
      • Market Analysis, 2012 – 2017 and Forecast, 2018 – 2023 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Latin America
      • Market Analysis, 2012 – 2017 and Forecast, 2018 – 2023 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Middle East and Africa
      • Market Analysis, 2012 – 2017 and Forecast, 2018 – 2023 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Global Graft Versus Host Disease (GVHD) Market – Opportunity Analysis Index, By Product Type, By Disease Type By Route of Administration and Region, 2018 – 2023
  2. North America Graft Versus Host Disease (GVHD) Market Analysis, 2012 – 2017 and Forecast, 2018 – 2023 (Revenue, USD Mn)
    • Product Type Analysis 2012 – 2017 and Forecast 2018 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
      • Monoclonal antibodies
      • Tyrosine kinase inhibitors
      • mTOR inhibitors
      • Etanercept
      • Thalidomide
    • Disease Type Analysis 2012 – 2017 and Forecast 2018 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Acute graft vs. host disease (aGvHD)
      • Chronic graft vs. host disease (cGvHD)
    • Route of Administration Analysis 2012 – 2017 and Forecast 2018 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Oral
      • Parenteral
    • Country Analysis 2017 and Forecast 2018 – 2023 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
      • US.
      • Canada
    • North America Graft Versus Host Disease (GVHD) Market – Opportunity Analysis Index, By Product, By Disease Type, By Route of Administration and Country, 2018 – 2023
    • North America Graft Versus Host Disease (GVHD) Market Dynamics – Trends
  3. Europe Graft Versus Host Disease (GVHD) Market Analysis, 2012 – 2017 and Forecast, 2018 – 2023 (Revenue, USD Mn)
    • Product Type Analysis 2012 – 2017 and Forecast 2018 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
      • Monoclonal antibodies
      • Tyrosine kinase inhibitors
      • mTOR inhibitors
      • Etanercept
      • Thalidomide
    • Disease Type Analysis 2012 – 2017 and Forecast 2018 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Acute graft vs. host disease (aGvHD)
      • Chronic graft vs. host disease (cGvHD)
    • Route of Administration Analysis 2012 – 2017 and Forecast 2018 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Oral
      • Parenteral
    • Country Analysis 2012 – 2017 and Forecast 2018 – 2023 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
      • Germany
      • UK
      • France
      • Spain
      • Italy
      • Russia
      • Poland
      • Rest of Europe
    • Europe Graft Versus Host Disease (GVHD) Market – Opportunity Analysis Index, By Product, By Disease Type, By Route of Administration and Country, 2018 – 2023
    • Europe Graft Versus Host Disease (GVHD) Market Dynamics – Trends
  4. Asia-Pacific Graft Versus Host Disease (GVHD) Market Analysis, 2012 – 2017 and Forecast, 2018 – 2023 (Revenue, USD Mn)
    • Product Type Analysis 2012 – 2017 and Forecast 2018 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
      • Monoclonal antibodies
      • Tyrosine kinase inhibitors
      • mTOR inhibitors
      • Etanercept
      • Thalidomide
    • Disease Type Analysis 2012 – 2017 and Forecast 2018 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Acute graft vs. host disease (aGvHD)
      • Chronic graft vs. host disease (cGvHD)
    • Route of Administration Analysis 2012 – 2017 and Forecast 2018 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Oral
      • Parenteral
    • Country Analysis 2012 – 2017 and Forecast 2018 – 2023 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
      • Japan
      • China
      • India
      • ASEAN
      • Australia & New Zealand
      • Rest of Asia-Pacific
    • Asia-Pacific Graft Versus Host Disease (GVHD) Market – Opportunity Analysis Index, By Product, By Disease Type, By Route of Administration and Country, 2018 – 2023
    • Asia-Pacific Graft Versus Host Disease (GVHD) Market Dynamics – Trends
  5. Latin America Graft Versus Host Disease (GVHD) Market Analysis, 2012 – 2012 – 2012 – 2017 and Forecast, 2018 – 2023 (Revenue, USD Mn)
    • Product Type Analysis 2012 – 2017 and Forecast 2018 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
      • Monoclonal antibodies
      • Tyrosine kinase inhibitors
      • mTOR inhibitors
      • Etanercept
      • Thalidomide
    • Disease Type Analysis 2012 – 2017 and Forecast 2018 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Acute graft vs. host disease (aGvHD)
      • Chronic graft vs. host disease (cGvHD)
    • Route of Administration Analysis 2012 – 2017 and Forecast 2018 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Oral
      • Parenteral
    • Country Analysis 2012 – 2017 and Forecast 2018 – 2023 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
      • Brazil
      • Mexico
      • Argentina
      • Venezuela
      • Rest of Latin America
    • Latin America Graft Versus Host Disease (GVHD) Market – Opportunity Analysis Index, By Product, By Disease Type, By Route of Administration and Country, 2018 – 2023
    • Latin America Graft Versus Host Disease (GVHD) Market Dynamics – Trends
  6. Middle East and Africa Graft Versus Host Disease (GVHD) Market Analysis, 2012 – 2017 and Forecast, 2018 – 2023 (Revenue, USD Mn)
    • Product Type Analysis 2012 – 2017 and Forecast 2018 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
      • Monoclonal antibodies
      • Tyrosine kinase inhibitors
      • mTOR inhibitors
      • Etanercept
      • Thalidomide
    • Disease Type Analysis 2012 – 2017 and Forecast 2018 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Acute graft vs. host disease (aGvHD)
      • Chronic graft vs. host disease (cGvHD)
    • Route of Administration Analysis 2012 – 2017 and Forecast 2018 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Oral
      • Parenteral
    • Country Analysis 2012 – 2017 and Forecast 2018 – 2023 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
      • Gulf Cooperation Council (GCC) Countries
      • Israel
      • South Africa
      • Rest of MEA
    • MEA Graft Versus Host Disease (GVHD) Market – Opportunity Analysis Index, By Product, By Disease Type, By Route of Administration and Country, 2018 – 2023
    • MEA Graft Versus Host Disease (GVHD) Market Dynamics – Trends
  7. Competition Landscape
    • Strategic Dashboard of Top Market Players
    • Company Profiles (Introduction, Financial Analysis, Drug Class & Service Offerings, Key Developments, Strategies, and SWOT Analysis)
      • Hoffmann-La Roche Ltd.
      • AbbVie
      • Bristol-Myers Squibb
      • Pfizer
      • Baxter
      • Novartis
      • Eli Lilly
      • Shire
      • Allergan
      • Caladrius
      • Eisai
      • Anterogen
  1. Research Methodology
  2. Key Assumptions and Acronyms

Report

Company Profile

  • Novartis AG (Switzerland)
  • Merck & Co. (U.S)
  • Soligenix, Inc. (U.S)
  • Mesoblast Ltd (Australia)
  • Sanofi (France)
  • Neovii Biotech GmbH (Switzerland)
  • Astellas Pharma Inc. (Japan)
  • Mallinckrodt Pharmaceuticals (UK)

Description

The global graft versus host disease treatment market expected to grow at a CAGR of 7.08% during the forecast period 2021-2027. Graft versus host disease is an immune-mediated disease. It is the medical complication in which there would be a complex interaction between the donor and the adaptive immunity of the recipient. The disease occurs when the bone marrow or the stem cells are transplanted. The treatment using the stem cells and bone marrow are used in the reconstruction of the damaged cells which surround the cancer cells. It is also used in the during solid organ transplantation. The chances of developing graft versus host disease is more in the allogeneic transplantation.

ASIA PACIFIC OFFICE

Precision Business Insights, 5th Floor, Mohan’s Elite, Opp : Bharat Petroleum Pump, Khanamet Road, Hitech City, Hyderabad – 500084

EUROPE OFFICE

Precision Business Insights, Kemp House, 152 – 160 City Road, London EC1V 2NX